ProGen's R&D competitiveness in developing bi-specific antibodies expands to various fields, including immunotherapy, diabetes drugs, and new drugs for obesity. ProGen has started joint research with Yuhan Corp. to develop immunotherapy, and the company has also entered phase 2 trials for in-house developed drugs for diabetes and new drugs for obesity. Furthermore, ProGen has signed a business agreement with AbTis, a subsidiary of Dong-A ST, to develop bi-specific antibody-drug conjugates (ADC).

Sources said on July 16th that earlier this month, ProGen signed a comprehensive R&D collaboration agreement with Yuhan Corp. to develop innovative new drug candidates. These companies have established a new drug